Literature DB >> 1563212

The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function.

R K Portenoy1, H T Thaler, C E Inturrisi, H Friedlander-Klar, K M Foley.   

Abstract

Morphine-6-glucuronide is a metabolite of morphine that binds to the opioid receptor and is analgesic in animals and humans. Although accumulation of morphine-6-glucuronide in patients with renal insufficiency has been implicated in morphine toxicity, the contribution of the metabolite to morphine analgesia in patients with normal renal function has not been established. To evaluate this contribution, we repeatedly sampled blood and assessed effects during and after a loading infusion with morphine (mean duration, 168 minutes) in 14 patients with chronic pain, all of whom had normal serum creatinine levels. Plasma concentrations of morphine and morphine-6-glucuronide were assayed by use of high performance liquid chromatography with electrochemical detection. Patients were divided into three groups on the basis of the molar concentration ratio of morphine-6-glucuronide:morphine from the start of the infusion until 240 minutes later: Group 1 (n = 5) had a mean ratio greater than or equal to 0.7:1; group 2 (n = 4) had a mean ratio less than 0.7:1 but greater than or equal to 0.4:1; and group 3 (n = 5) had a mean ratio less than 0.4:1. Time-effect plots revealed that average and peak relief were greater in group 1 than group 2 and greater in group 2 than group 3. For all patients, mean morphine-6-glucuronide:morphine ratio throughout the study was significantly correlated with mean pain relief (r = 0.611, p less than 0.02). These data suggest that morphine-6-glucuronide contributes to morphine analgesia in patients with normal renal function. The role of the metabolite should be considered when morphine is used clinically.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1563212     DOI: 10.1038/clpt.1992.42

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

1.  The pharmacogenetics of codeine pain relief in the postpartum period.

Authors:  M Baber; S Chaudhry; L Kelly; C Ross; B Carleton; H Berger; G Koren
Journal:  Pharmacogenomics J       Date:  2015-03-10       Impact factor: 3.550

2.  Paradoxical pain.

Authors:  D Bowsher
Journal:  BMJ       Date:  1993-02-20

3.  Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes.

Authors:  M Shipkova; C P Strassburg; F Braun; F Streit; H J Gröne; V W Armstrong; R H Tukey; M Oellerich; E Wieland
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

Review 4.  Opioid analgesics: comparative features and prescribing guidelines.

Authors:  N I Cherny
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 5.  Morphine-6-glucuronide: an analgesic of the future?

Authors:  J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Morphine-6beta-glucuronide modulates the expression of inducible nitric oxide synthase.

Authors:  D T Lysle; K A Carrigan
Journal:  Inflammation       Date:  2001-08       Impact factor: 4.092

7.  Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.

Authors:  Glynn A Morrish; David J R Foster; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

8.  [Drug therapy for tumor pain I. Properties of non-opioids and opioids.].

Authors:  N I Cherny; R K Portenoy; M Raber; M Zenz
Journal:  Schmerz       Date:  1994-12       Impact factor: 1.107

9.  Extended-release formulation of morphine for subcutaneous administration.

Authors:  T Kim; J Kim; S Kim
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  HIM-herbal ingredients in-vivo metabolism database.

Authors:  Hong Kang; Kailin Tang; Qi Liu; Yi Sun; Qi Huang; Ruixin Zhu; Jun Gao; Duanfeng Zhang; Chenggang Huang; Zhiwei Cao
Journal:  J Cheminform       Date:  2013-05-31       Impact factor: 5.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.